Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice

Brain Research

Volumn 1345, Issue , 2010, Pages 213-220

  Liu, Jing ^a   Wang, Ming Wei ^a   Gu, Ping ^a   Ma, Qin Ying ^a   Wang, Yan Yong ^a   Geng, Yuan ^a   Yuan, Zhen Yun ^a   Cui, Dong Sheng ^a   Zhang, Zhong Xia ^a   Ma, Lin ^a   Zhang, Bao Hua ^a   Zhou, Mei Gang ^a   Zhu, Ai Ping ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Aging; iNOS; Microglia; MPTP; Parkinson's disease; SAMP8

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; NERVE PROTEIN; TYROSINE 3 MONOOXYGENASE; CD11B ANTIGEN; NOS2 PROTEIN, MOUSE;

AGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CONVALESCENCE; CORPUS STRIATUM; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; SENESCENCE ACCELERATED MOUSE; AGING; ANIMAL; BRAIN; CELL COUNT; CHEMICALLY INDUCED; MESENCEPHALON; METABOLISM; MOTOR ACTIVITY; MUTANT MOUSE STRAIN; NERVE CELL; PARKINSONISM; PATHOLOGY; TIME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AGING; ANIMALS; ANTIGENS, CD11B; BRAIN; CELL COUNT; CORPUS STRIATUM; DOPAMINE; MALE; MESENCEPHALON; MICE; MICE, MUTANT STRAINS; MICROGLIA; MOTOR ACTIVITY; NERVE DEGENERATION; NEURONS; NITRIC OXIDE SYNTHASE TYPE II; PARKINSONIAN DISORDERS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; MUS;

EID: 77955518879     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.05.043     Document Type: Article

References (33)

1. S.F. Ali, S.N. David, G.D. Newport, J.L. Cadet, and W. Slikker Jr. MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels Synapse 18 1994 27 34
2. E. Bezard, and C.E. Gross Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach Prog. Neurobiol. 55 1998 93 116
3. E. Bezard, M. Jaber, F. Gonon, et al. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurodegeneration in the mouse Eur. J. Neurosci. 12 2000 2892 2900
4. M.L. Block, and J.S. Hong Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism Prog. Neurobiol. 76 2005 77 98
5. J. Bove, D. Prou, C. Perier, and S. Przedborski Toxin-induced models of Parkinson's disease NeuroRx 2 2005 484 494
6. T.J. Collier, J. Lipton, B.F. Daley, S. Palfi, Y. Chu, C. Sortwell, R.A. Bakay, J.R. Sladek, and J.H. Kordower Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism Neurobiol. Dis. 26 2007 56 65
7. J.A. Cooper, H.J. Sagar, N. Jordan, N.S. Harvey, and E.V. Sullivan Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability Brain 114 1991 2095 2122
8. J.T. Coyle, and P. Puttfarcken Oxidative stress, glutamate, and neurodegenerative disorders Science 262 1993 689 695
9. T. Dehmer, J. Lindenau, S. Haid, J. Dichgans, and J.B. Schulz Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo J. Neurochem. 74 2000 2213 2216
10. Y. He, S. Appel, and W. Le Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum Brain Res. 909 2001 187 193
11. A.J. Herrera, M. Tomas-Camardiel, J.L. Venero, J. Cano, and A. Machado Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons J. Neural Transm. 112 2005 111 119
12. T. Kawamata, I. Akiguchi, H. Yagi, M. Irino, H. Suqiyama, H. Akiyama, A. Shimada, M. Takemura, M. Ueno, T. Kitabayashi, K. Ohnishi, N. Seriu, K. Hiquchi, M. Hosokawa, and T. Takeda Neuropathological studies on strains of senescence-accelerated mice (SAM) with age-related deficits in learning and memory Exp. Gerontol. 32 1997 161 169
13. T. Kawasaki, Y. Ago, T. Kitao, T. Nashida, A. Takagi, K. Takuma, and T. Matsuda A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl} azetidin-3-olmaleate), prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity in mice Neuropharmacology 55 2008 654 660
14. C. Knott, G. Stern, and G.P. Wilkin Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2 Mol. Cell. Neurosci. 16 2000 724 739
15. B.E. Levin, M.M. Llabre, and W.J. Weiner Cognitive impairments associated with early Parkinson's disease Neurology 39 1989 557 561
16. B. Liu Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease AAPS J. 8 2006 E606 E621
17. J. Liu, Y.Y. Wang, L. Liu, Q.D. Wang, Z.Y. Yuan, Z.X. Zhang, P. Gu, and M.W. Wang Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse Neurosci. Lett. 448 2008 184 188
18. P.L. McGeer, and E.G. McGeer Inflammation and neurodegeneration in Parkinson's disease Parkinsonism Relat. Disord. 10 Suppl 1 2004 S3 S7
19. M. Miyamoto Characteristics of age-related behavioral changes in senescence-accelerated mouse SAMP8 and SAMP10 Exp. Geront. 32 1997 139 148
20. S. Ohashi, A. Mori, N. Kurihara, Y. Mitsumoto, and M. Nakai Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice Neurosci. Lett. 401 2006 183 187
21. V.H. Perry, C. Cunningham, and C. Holmes Systemic infections and inflammation affect chronic neurodegeneration Nat. Rev. Immunol. 7 2007 161 167
22. G.A. Ricaurte, I. Irwin, L.S. Forno, L.E. Delanney, E. Langston, and J.W. Langston Aging and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra Brain Res. 403 1987 43 51
23. E. Rousselet, C. Joubert, J. Callebert, et al Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice Neurobiol. Dis. 14 2003 218 228
24. N. Schmidt, and B. Ferger Neurochemical findings in the MPTP model of Parkinson's disease J. Neural Transm. 108 2001 1263 1282
25. M. Sedelis, R.K. Schwarting, and J.P. Huston Behavioral phenotyping of the MPTP mouse model of Parkinson's disease Behav. Brain Res. 125 2001 109 125
26. S. Sugama, L. Yang, B.P. Cho, L.A. Degiorgio, S. Lorenzl, D.S. Albers, M.F. Beal, B.T. Volpe, and T.H. Joh Age-related microglial activation in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice Brain Res. 964 2003 288 294
27. T. Takeda, M. Hosokawa, and K. Higuchi Senescence-accelerated mouse (SAM): a novel murine model of senescence Exp. Gerontol. 32 1997 105 109
28. A.E. Taylor, J.A. Saint-Cyr, and A.E. Lang Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow Brain 109 1986 845 883
29. von Bohlen Und Halbach O Animal models of Parkinson's disease in vivo review Neurodegener. Dis. 2 2005 313 320
30. Y. Watanabe, H. Kato, and T. Araki Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease Metab. Brain Dis. 23 2008 51 69
31. P.S. Whitton Inflammation as a causative factor in the aetiology of Parkinson's disease Br. J. Pharmacol. 150 2007 963 976
32. D.C. Wu, V. Jackson-Lewis, M. Vila, K. Tieu, P. Teismann, C. Vadseth, D.K. Choi, H. Ischiropoulos, and S. Przedborski Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease J. Neurosci. 22 2002 1763 1771
33. D.C. Wu, P. Teismann, K. Tieu, M. Vila, V. Jackson-Lewis, H. Ischiropoulos, and S. Przedborski NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease Proc. Natl Acad. Sci. USA 100 2003 6145 6150